Xencor Inc XNCR

Healthcare Biotechnology

Xencor, Inc. is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases. More than 20 candidates engineered with its XmAb technology are in clinical development, and three XmAb medicines are marketed by partners. Its XmAb engineering technology enables small changes to a protein structure that result in new mechanisms of therapeutic action. Its wholly owned development candidates include Vudalimab, XmAb819, XmAb808, and XmAb541. Candidates co-developed with partners include Plamotamab. Candidates advanced by partners include Xaluritamig (AMG 509), ASP2138, JNJ-9401, JNJ-1493, and Novartis XmAb undisclosed antibody candidate. Its cytokine drug candidates in clinical development consist of fbalropendekin alfa (XmAb306/RG6323), XmAb564, and XmAb662. Its other clinical-stage drug candidates consist of Obexelimab, AIMab7195 (XmAb7195), and Xpro1595. Vudalimab is a bispecific antibody that targets PD-1 and CTLA-4.

NDAQ:XNCR - Post by User

Xencor Inc

<< Previous

Bullboard Posts

Next >>

(297)
•••

Post by whytestockson Apr 09, 2024 11:00pm

54 Views

Post# 35980452

Xencor Appoints Bart Cornelissen as Chief Financial Officer

JUST IN: $XNCR Xencor Appoints Bart Cornelissen as Chief Financial OfficerXencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced the appointment of Bart Cornelissen to senior vice president and chief financial officer. Mr. Cornelissen has more than 2...XNCR - Xencor Appoints Bart Cornelissen as Chief Financial Officer

<< Previous

Bullboard Posts

Next >>

Corus reports Q1 profit drop in the face of falling revenue